Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of ZYN-001 in Tourette Syndrome.

Trial Profile

Phase II study of ZYN-001 in Tourette Syndrome.

Phase of Trial: Phase II

Latest Information Update: 09 Jan 2018

At a glance

  • Drugs ZYN 001 (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jan 2018 New trial record
    • 03 Jan 2018 According to the Zynerba Pharmaceuticals media release, company expects to initiate this trial late in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top